Latest & greatest articles for influenza

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on influenza or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on influenza and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for influenza

701. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. (Abstract)

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. In 1997, pathogenic avian influenza A/Hong Kong/97 (H5N1) viruses emerged as a pandemic threat to human beings. A non-pathogenic variant, influenza A/Duck/Singapore/97 (H5N3), was identified as a leading vaccine candidate. We did an observer-blind, phase I, randomised trial in healthy volunteers to assess safety (...) , tolerability, and antigenicity of MF59-adjuvanted and non-adjuvanted vaccines.32 participants were randomly assigned MF59, and 33 non-adjuvanted vaccine. Two doses were given 3 weeks apart, of 7.5, 15, or 30 microg haemagglutinin surface-antigen influenza A H5N3 vaccine. Antibody responses were measured by haemagglutination inhibition, microneutralisation, and single radial haemolysis (SRH). The primary outcome was geometric mean antibody titre 21 days after vaccination.The A/Duck/SIngapore vaccines were

2001 Lancet Controlled trial quality: uncertain

702. Economic evaluation of zanamivir (relenza) for the treatment of influenza

Economic evaluation of zanamivir (relenza) for the treatment of influenza Economic evaluation of zanamivir (relenza) for the treatment of influenza Economic evaluation of zanamivir (relenza) for the treatment of influenza Brady B, McAuley L, Shukla V K Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Brady B, McAuley L, Shukla V K (...) . Economic evaluation of zanamivir (relenza) for the treatment of influenza. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Technology Report Issue 13. 2001 Authors' objectives The objective of this report is to assess the cost-effectiveness of zanamivir (Relenza(R))for treating influenza in adults. Cost-effectiveness is assessed for the general population as well as for those at-risk of developing complications related to influenza. Authors' conclusions From the perspective

2001 Health Technology Assessment (HTA) Database.

703. Oseltamivir for the treatment of suspected influenza: a clinical and economic assessment

Oseltamivir for the treatment of suspected influenza: a clinical and economic assessment Oseltamivir for the treatment of suspected influenza: a clinical and economic assessment Oseltamivir for the treatment of suspected influenza: a clinical and economic assessment Canadian Coordinating Office for Health Technology Assessment Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation Canadian Coordinating Office for Health Technology Assessment. Oseltamivir for the treatment of suspected influenza: a clinical and economic assessment. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2001: 90 Authors' objectives The aims of this report are: (1) To perform a systematic review of published and unpublished clinical studies to assess and quantify, using a meta-analysis if appropriate, the efficacy and effectivenessa

2001 Health Technology Assessment (HTA) Database.

704. Do neuraminidase inhibitors prevent influenza?

Do neuraminidase inhibitors prevent influenza? Do neuraminidase inhibitors prevent influenza? Do neuraminidase inhibitors prevent influenza? Husereau D R Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Husereau D R. Do neuraminidase inhibitors prevent influenza? Ottawa: Canadian Coordinating Office for Health Technology Assessment/Office (...) Canadien de Coordination de l'Evaluation des Technologies de la Sante (CCOHTA) 2001: 4 Authors' objectives To summarise the available evidence on two neuraminidase inhibitors (zanamivir and oseltamivir) for the prevention of influenza. Authors' conclusions - Two neuraminidase inhibitors, zanamivir and oseltamivir, are well-tolerated and reduce the likelihood of contracting influenza in both healthy individuals and those who are at risk for developing complications. - There is insufficient evidence

2001 Health Technology Assessment (HTA) Database.

705. Oseltamivir for the treatment of suspected influenza: a clinical and economic assessment

Oseltamivir for the treatment of suspected influenza: a clinical and economic assessment Oseltamivir for the treatment of suspected influenza: a clinical and economic assessment Oseltamivir for the treatment of suspected influenza: a clinical and economic assessment Husereau D R, Brady B, McGeer A Authors' objectives To perform a systematic review to assess and quantify the efficacy and effectiveness of oseltamivir in individuals who are suspected of having influenza. In addition, to assess (...) the cost-effectiveness of treating suspected influenza with oseltamivir in a primary care setting where standard treatment is no active medical intervention. Searching MEDLINE, EMBASE, HealthSTAR, Pascal, SciSearch and TOXLINE were searched from 1997 to 2001. The websites of regulatory agencies, health technology assessment and near technology assessment agencies were also searched. The search terms were provided in the paper. Narrative and systematic reviews, articles and conference abstracts were

2001 DARE.

706. Evaluation of a mass influenza vaccination campaign

Evaluation of a mass influenza vaccination campaign Evaluation of a mass influenza vaccination campaign Evaluation of a mass influenza vaccination campaign Takahashi H, Tanaka Y, Ohyama T, Sunagawa T, Nakashima K, Schmid G P, Okabe N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability (...) of the study and the conclusions drawn. Health technology The health technology studied was a mass influenza vaccination campaign for people aged 3 years or older. The vaccine used was Influenza HA vaccine (1 mL vial containing A/Beijing/262/95 200CCA/ mL, A/Sydney/5/97 350 CCA/mL, and B/Shangdong 300CCA/mL). The vaccine was administered subcutaneously at a dose of 0.5 mL for adults, 0.3 mL for children aged 6 to 12 years, and 0.2 mL for children aged 3 to 5 years. Type of intervention Primary prevention

2001 NHS Economic Evaluation Database.

707. Economic evaluation of Haemophilus influenzae type b vaccination in Slovenia

Economic evaluation of Haemophilus influenzae type b vaccination in Slovenia Economic evaluation of Haemophilus influenzae type b vaccination in Slovenia Economic evaluation of Haemophilus influenzae type b vaccination in Slovenia Pokorn M, Kopac S, Neubauer D, Cizman M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology The health intervention examined in the study was Haemophilus influenzae type b (Hib) vaccination in children under 5 years of age. Type of intervention Vaccination. Economic study type Cost-effectiveness analysis; Cost-benefit analysis. Study population The study population comprised a birth cohort of children younger than 5 years of age. Setting The setting was community. The economic study was conducted

2001 NHS Economic Evaluation Database.

708. Cost-effectiveness of combined outreach for the pneumococcal and influenza vaccines

Cost-effectiveness of combined outreach for the pneumococcal and influenza vaccines Cost-effectiveness of combined outreach for the pneumococcal and influenza vaccines Cost-effectiveness of combined outreach for the pneumococcal and influenza vaccines Weaver M, Krieger J, Castorina J, Walls M, Ciske S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study investigated the implementation of a community-based outreach intervention to promote pneumococcal and influenza vaccines in elderly people. Type of intervention Primary prevention. Economic study type Cost-utility analysis. Study population The study population comprised people aged 65 years or older who were residing in the targeted ZIP code areas and who returned

2001 NHS Economic Evaluation Database.

709. Cost-benefit analysis of a Haemophilus influenzae type B meningitis prevention programme in the Philippines

Cost-benefit analysis of a Haemophilus influenzae type B meningitis prevention programme in the Philippines Cost-benefit analysis of a Haemophilus influenzae type B meningitis prevention programme in the Philippines Cost-benefit analysis of a Haemophilus influenzae type B meningitis prevention programme in the Philippines Limcangco M R M T, Armour C L, Salole E G, Taylor S J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two strategies against Haemophilus Influenzae Type B (Hib) Meningitis were compared: a government-funded vaccination programme, and a no vaccination programme. Type of intervention Primary prevention. Economic study type Cost-benefit analysis. Study population The study population was a birth cohort

2001 NHS Economic Evaluation Database.

710. Cost-effectiveness of influenza vaccination in high-risk children in Argentina

, haemoglobinopathies or immunosuppression. Children receiving aspirin therapy were considered at risk for developing Reye's syndrome after influenza infection. Setting The setting was the community. The economic study was carried out in Argentina. Dates to which data relate The effectiveness and resource use data were derived from studies published between 1960 to 2000. The price year was 1998. Source of effectiveness data The effectiveness evidence was derived from published studies, augmented by the authors (...) Cost-effectiveness of influenza vaccination in high-risk children in Argentina Cost-effectiveness of influenza vaccination in high-risk children in Argentina Cost-effectiveness of influenza vaccination in high-risk children in Argentina Dayan G H, Nguyen V H, Debbag R, Gomez R, Wood S C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed

2001 NHS Economic Evaluation Database.

711. Influenza vaccination, hospitalizations, and costs among members of a Medicare managed care plan

Influenza vaccination, hospitalizations, and costs among members of a Medicare managed care plan Influenza vaccination, hospitalizations, and costs among members of a Medicare managed care plan Influenza vaccination, hospitalizations, and costs among members of a Medicare managed care plan Davis J W, Lee E, Taira D A, Chung R S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study evaluated the vaccination of persons aged 65 years or older against influenza. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population The population comprised all members of a Medicare managed care plan who were aged 65 years or older. Setting The setting was not specified, although

2001 NHS Economic Evaluation Database.

712. A cost-benefit analysis of anti-influenza vaccination in a company in Italy (Snamprogetti)

A cost-benefit analysis of anti-influenza vaccination in a company in Italy (Snamprogetti) A cost-benefit analysis of anti-influenza vaccination in a company in Italy (Snamprogetti) A cost-benefit analysis of anti-influenza vaccination in a company in Italy (Snamprogetti) Colombo G L, Nicosia V, Lesma A, Madera A, Caruggi M, Serra G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A campaign for vaccination against influenza in workplaces was studied. Type of intervention Vaccination. Economic study type Cost-benefit analysis. Study population The study population comprised employees of an Italian company (Snamprogetti). Setting The setting was the workplace. The economic study was carried out in the offices of Snamprogetti

2001 NHS Economic Evaluation Database.

713. Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults Full Text available with Trip Pro

with oseltamivir; Guillain-Barre syndrome; hospitalisation for influenza; proportionate improvement with oseltamivir; physician prescribing oseltamivir within 48 hours; medical visit for ILI in supportive care patients; medical visit for ILI for patients receiving treatment; medical visit for ILI in vaccination group; medical visit for side effects; and health-related quality of life. Study designs and other criteria for inclusion in the review Not reported. Sources searched to identify primary studies (...) . Investigation of differences between primary studies Not reported. Results of the review The following values, expressed as probabilities, were used in the model: development of ILI, 0.49 (range: 0.21 - 0.50); compliance with oseltamivir, 0.95 (range: 0.5 - 1); Guillain-Barre syndrome, 1 x10^-6 (range: 0.5 x10^-6 - 9 x10^-6); hospitalisation for influenza, 0.00024 (range: 0.00018 - 0.024); proportionate improvement with oseltamivir, 0.213 (range: 0.18 - 0.248); physician prescribing oseltamivir within 48

2001 NHS Economic Evaluation Database.

714. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza

effectiveness level; number of health care provider visits per illness episode; hospitalisation rate for influenza complications; death rate; work absenteeism for vaccination; likelihood of work loss for vaccination; work absenteeism for potential side effects due to vaccination; number of health care provider visits for potential side effects; Guillain-Barre syndrome rate; vaccine effectiveness in year with good match; vaccine effectiveness in year with poor match; and likelihood of good vaccine match (...) ). The cost of a health care providers visit, including procedures and medications and the cost of an initial outpatient visit for influenza illness, including the cost of physicians' fees and medication were both estimated to be $102 (range: $80 - $123). The cost per hospital admission for influenza-associated complications was estimated at $5,669 (range: $3,669 - $7,669), and medical care costs per episode of vaccine-associated Guillain-Barre syndrome, were estimated at $11,0674. These costs were

2001 NHS Economic Evaluation Database.

715. Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients

Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients Griffin A D, Perry A S, Fleming D M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technology was the use of zanamivir 10mg twice daily for 5 days in the treatment of influenza in high-risk patients. Type of intervention Treatment. Economic study type Cost-effectiveness analysis; cost-utility analysis. Study population The study population was a cohort of high-risk patients drawn from

2001 NHS Economic Evaluation Database.

716. Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children

Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children Luce B R, Zangwill K M, Palmer C S, Mendelman P M, Yan L H, Wolff M C, Cho I S, Marcy S M, Iacuzio D, Belshe R B Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of a live, attenuated, trivalent, intranasal influenza vaccine was examined. The vaccine contained 10^6.7 to 10^7.0 tissue culture infective dose50/dose of each of three attenuated strains that matched the antigens

2001 NHS Economic Evaluation Database.

717. Vaccines for preventing influenza in people with cystic fibrosis. (Abstract)

Vaccines for preventing influenza in people with cystic fibrosis. Viral respiratory tract infections in patients with cystic fibrosis have a deteriorating effect on their lung function and disease progression. Annual influenza vaccination is therefore commonly recommended for patients with cystic fibrosis.To assess the effectiveness of influenza vaccination for patients with cystic fibrosis.We have used the Cochrane Cystic Fibrosis and Genetic Disorders Group specialist trials register which (...) comprises references identified from comprehensive electronic database searches, hand searching relevant journals and abstract books of conference proceedings and communication to the drug companies marketing influenza vaccines.All randomised and pseudorandomised trials (published or unpublished) comparing any influenza vaccine with a placebo or with another type of influenza vaccine.Both reviewers independently assessed trial quality and extracted data. Additional information were obtained

2000 Cochrane

718. Vaccines for preventing influenza in healthy adults. Full Text available with Trip Pro

Vaccines for preventing influenza in healthy adults. To identify, retrieve and assess all studies evaluating the effects of vaccines on influenza in healthy adults. To assess the effectiveness of vaccines in preventing cases of influenza in healthy adults. To estimate the frequency of adverse effects associated with influenza vaccination in healthy adults.MEDLINE was searched using the strategy of the Cochrane Acute Respiratory Infections Group. The bibliography of retrieved articles (...) , the Cochrane Controlled Trials Register (CCTR), and EMBASE (1990 to 1997) were also searched. Handsearch of the journal Vaccine from its first issue to the end of 1997 (Jefferson and Jefferson, 1996; Jefferson, 1998). We wrote to vaccine manufacturers and first or corresponding authors of studies in the review.Any randomised or quasi-randomised studies comparing influenza vaccines in humans with placebo, control vaccines or no intervention, or comparing types, doses or schedules of influenza vaccine. Live

2000 Cochrane

719. Haemophilus influenzae oral vaccination against acute bronchitis. Full Text available with Trip Pro

Haemophilus influenzae oral vaccination against acute bronchitis. To assess the effects of an oral whole cell nontypeable Haemophilus influenzae (NTHi) vaccine in protecting against recurrent episodes of bronchitis.We searched the Cochrane trials register, MEDLINE, Extramed, ISI Current Contents, Carl Uncover and contacted investigators of the studies.Randomised trials comparing the effects of an oral monobacterial NTHi vaccine on patients with recurrent exacerbations of bronchitis were (...) included when there was overt matching of the vaccine and placebo groups on clinical grounds.Two reviewers extracted data and assessed trial quality independently from original records and publications for incidence and severity of bronchitis episodes and carriage rate of nontypeable Haemophilus influenzae in the upper respiratory tract every three months following vaccination.Six trials were included in the study with a total of 440 participants. Oral vaccination using a monobacterial whole cell

2000 Cochrane

720. Amantadine and rimantadine for preventing and treating influenza A in adults. (Abstract)

Amantadine and rimantadine for preventing and treating influenza A in adults. Amantadine hydrochloride and rimantadine hydrochloride have antiviral properties, but they are not widely used due to a lack of knowledge of their properties and concerns about possible adverse effects. The objective of this review was to assess the effects and safety of amantadine and rimantadine in healthy adults.We searched the Cochrane Controlled Trials Register, Medline, Embase and reference lists of articles. We (...) also contacted manufacturers, researchers and authors.Randomised and quasi-randomised studies comparing amantadine and/or rimantadine with placebo, control antivirals or no intervention, or comparing doses or schedules of amantadine and/or rimantadine in healthy adults.For prevention trials the numbers of participants with clinically defined influenza, with serologically confirmed clinical influenza A and adverse effects were analysed. Analysis for treatment trials was of the mean duration of fever

2000 Cochrane